The U.K.’s National Institute for Health and Care Excellence recommended the use of Firmagon (degarelix) for men with advanced hormone-dependent prostate cancer with spinal metastases. This announcement follows a three-year review process and NICE’s most recent draft Appraisal Consultation Document published in June 2015, which recommended against the use of Firmagon within its marketing authorization...
In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.
